U.S. stock futures were higher this morning, with the Dow futures gaining around 0.1% on Wednesday.Shares of STAAR Surgical Co (NASDAQ:STAA) fell sharply in pre-market trading after the company reported worse-than-expected fourth-quarter financial results.Staar Surgical reported quarterly losses of 13 cents per share which missed the analyst consensus estimate of earnings of 6 cents per share. The company reported quarterly sales of $57.801 million which missed the analyst consensus estimate of $75.370 mill ...

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential opportunities for traders [1] Premarket Gainers - Brand Engagement Network, Inc. (BNAI) is up 20% at $51.61 [3] - Latham Group, Inc. (SWIM) is up 20% at $7.79 [3] - Evolus, Inc. (EOLS) is up 14% at $4.74 [3] - Edesa Biotech, Inc. (EDSA) is up 11% at $4.86 [3] - 20/20 Biolabs, Inc. (AIDX) is up 11% at $3.28 [3] - DeFi Development Corp. (DFDV) is up 9% at $4.04 [3] - Accel Entertainment, Inc. (ACEL) is up 7% at $11.95 [3] - Solana Company (HSDT) is up 7% at $2.12 [3] - Nano-X Imaging Ltd. (NNOX) is up 6% at $2.76 [3] - Strive Asset Management, LLC (ASST) is up 5% at $8.81 [3] Premarket Losers - Battalion Oil Corporation (BATL) is down 28% at $19.67 [4] - TMD Energy Limited (TMDE) is down 24% at $3.03 [4] - Ascent Industries Co. (ACNT) is down 15% at $14.75 [4] - indie Semiconductor, Inc. (INDI) is down 14% at $2.71 [4] - WEBTOON Entertainment Inc. (WBTN) is down 13% at $9.98 [4] - STAAR Surgical Company (STAA) is down 10% at $17.00 [4] - Indonesia Energy Corporation Limited (INDO) is down 10% at $4.68 [4] - BiomX Inc. (PHGE) is down 7% at $4.52 [4] - Arbutus Biopharma Corporation (ABUS) is down 6% at $4.37 [4] - Global Interactive Technologies, Inc. (GITS) is down 6% at $2.43 [4]

Core Insights - The semiconductor tools supplier reported profits that exceeded expectations, driven by increased demand and a recovery in orders from China [1] Group 1 - The company experienced strengthened demand for its products, indicating a positive trend in the semiconductor industry [1] - There was a notable rebound in orders specifically from China, which is a significant market for semiconductor tools [1]

Financial Data and Key Metrics Changes - Total net sales for Q4 2025 were $57.8 million, compared to $49 million in the same quarter last year, driven by a lower than expected rebound in sales in China, partially offset by growth in the Americas and non-China APAC regions [21] - Gross profit margin for Q4 2025 was 75.7%, up from 64.7% in the prior year quarter, primarily due to cost reductions and the ramp-up of Swiss manufacturing [22] - Adjusted EBITDA for Q4 2025 was a loss of $200,000, an improvement from a loss of $20.8 million in the year-ago quarter [24] Business Line Data and Key Metrics Changes - China net sales in Q4 2025 were $17.5 million, up from $7.8 million in the year-ago quarter, although certain sub-distributors returned inventory, impacting sales [21] - Excluding China, net sales declined by 2% year-over-year, with the Americas up 18%, EMEA down 20%, and APAC ex-China up 2% in Q4 [22] Market Data and Key Metrics Changes - In China, demand for EVO ICL recovered at mid-single digit rates, but did not translate into net sales growth due to inventory reductions by distributors [10] - The U.S. business showed momentum despite a decline in laser vision correction procedures, with an expanded age range indication for EVO increasing the potential candidate pool by approximately 8 million [11] Company Strategy and Development Direction - The company aims for growth, improving profitability, and progress across its innovation pipeline in 2026, following a challenging 2025 [8] - Focus on enterprise-wide impacts and disciplined investing to drive profitability, including manufacturing improvements and optimizing average selling prices (ASPs) [13] - The launch of EVO+ in China and the expansion of the LIOLI injector for EVO ICL procedures are key components of the growth strategy [14][15] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the recovery in China and the potential for growth in 2026, despite previous macroeconomic challenges [10] - The company is focused on restoring revenue and maintaining cost discipline, with a target for profitability in FY 2026 [25][26] - Management emphasized the importance of innovation and the need to bring new products to market to maintain competitive advantage [85] Other Important Information - The company has engaged a search firm to find a permanent CEO, indicating a focus on leadership stability during this transition [8] - The company has no debt and ended Q4 2025 with approximately $187.5 million in cash equivalents and investments [25] Q&A Session Summary Question: Have the reductions in distributor inventory continued into Q1? - Management confirmed that inventory levels are stable and below contractual levels, indicating readiness for market recovery [32] Question: How does the health of the organization compare to pre-Alcon? - Management noted that expenses have been controlled since Q1 2025, and the organization is aligned around growth and profitability goals [36] Question: What is the expected growth for 2026? - Management refrained from providing specific guidance but expressed optimism about growth in both China and ex-China markets [44] Question: How is the company addressing inventory management in China? - Improved processes and weekly oversight of inventory levels have been implemented to prevent future buildups [47] Question: What is the strategy for U.S. growth versus China growth? - Management emphasized that while China remains the largest opportunity, the U.S. business is also seeing success and will continue to be a focus [53]

Financial Data and Key Metrics Changes - Total net sales for Q4 2025 were $57.8 million, compared to $49 million in the same quarter last year, driven by a lower than expected rebound in sales in China, partially offset by growth in the Americas and non-China APAC regions [21] - Gross profit margin for Q4 2025 was 75.7%, up from 64.7% in the prior year quarter, primarily due to the timing of cost recognition and cost reductions implemented earlier [22] - Adjusted EBITDA for Q4 2025 was a loss of $200,000, an improvement from a loss of $20.8 million in the year-ago quarter, attributed to higher gross profit and lower operating expenses [24] Business Line Data and Key Metrics Changes - China net sales in Q4 2025 were $17.5 million, up from $7.8 million in the year-ago quarter, although certain sub-distributors returned inventory, impacting sales [21] - Excluding China, net sales declined by 2% year-over-year, with the Americas up 18%, EMEA down 20%, and APAC ex-China up 2% in Q4 [22] Market Data and Key Metrics Changes - In China, demand for EVO ICL recovered at mid-single digit rates, but did not translate into net sales growth due to inventory reductions by distributors [10] - The U.S. business showed momentum despite a decline in laser vision correction procedures, with an expanded age range indication for EVO increasing the potential candidate pool by approximately 8 million [11] Company Strategy and Development Direction - The company aims for growth, improving profitability, and progress in its innovation pipeline for 2026, following a challenging 2025 [8] - Focus on enterprise-wide impacts and disciplined investing to drive profitability, including manufacturing improvements and optimizing average selling prices (ASPs) [13] - The company is advancing its ERP implementation and launching new products like EVO+ in China, which is expected to enhance margins and ASPs [14][15] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the recovery in China and the potential for growth in 2026, despite previous challenges [10] - The leadership team emphasized the importance of maintaining cost discipline while targeting profitability in FY 2026 [25] - Management acknowledged the need for continued innovation and the introduction of new products to capture market share [85] Other Important Information - The company has no debt and ended Q4 2025 with approximately $187.5 million in cash equivalents and investments [25] - The leadership structure has transitioned to a shared role of Interim Co-CEOs, aiming for continuity and alignment in strategy execution [6][8] Q&A Session Summary Question: Have the reductions in distributor inventory continued into Q1 or stabilized now that Alcon is behind? - Management reported stable inventory levels at distributors, slightly below the six-month contractual level, indicating readiness for market recovery [32] Question: How does the health of the organization today compare to pre-Alcon? - Management noted improved cost control and alignment within the organization post-Alcon, focusing on growth and profitability [36] Question: What is the expected growth for 2026 collectively? - Management refrained from providing specific guidance but expressed optimism about growth in both China and ex-China markets [44] Question: What structural changes have been implemented to prevent inventory buildups in China? - Enhanced processes for inventory management have been established, allowing for better visibility and control over distributor inventory levels [48] Question: How should we think about prioritization between U.S. growth and China growth? - Management emphasized that while the U.S. business is growing, China remains the largest opportunity, and investments will continue in both markets [53] Question: What is the growth algorithm moving forward? - Management indicated that while they do not expect to return to hyper-growth levels, they are working towards significant growth opportunities in 2026 [57]

Financial Data and Key Metrics Changes - Total net sales for Q4 2025 were $57.8 million, compared to $49 million in the year-ago quarter, driven by a lower than expected rebound in sales in China, partially offset by growth in the Americas and non-China APAC regions [20] - Gross profit margin for Q4 2025 was 75.7% of total net sales, compared to 64.7% in the prior year quarter, primarily due to cost reductions and the ramp-up of Swiss manufacturing [22] - Adjusted EBITDA for Q4 2025 was a loss of $200,000, an improvement from a loss of $20.8 million in the year-ago quarter, attributed to higher gross profit and lower operating expenses [24] Business Line Data and Key Metrics Changes - China net sales for Q4 2025 were $17.5 million, up from $7.8 million in the year-ago quarter, although certain sub-distributors returned inventory, impacting sales [20] - Excluding China, net sales declined by 2% year-over-year, with the Americas up 18%, EMEA down 20%, and APAC ex-China up 2% in Q4 [22] Market Data and Key Metrics Changes - In China, demand for EVO ICL recovered at mid-single digit rates, but did not translate into net sales growth due to inventory reductions by distributors [9] - The U.S. business showed momentum despite a decline in laser vision correction procedures, with an expanded age range indication for EVO increasing the potential candidate pool by approximately 8 million [10] Company Strategy and Development Direction - The company aims for growth, improving profitability, and meaningful progress across its innovation pipeline in 2026, following a difficult transition year in 2025 [6] - Focus on enterprise-wide impacts and new ways of working to increase decision-making velocity and operational efficiency [12] - The company is advancing its innovation strategy with the launch of EVO+ in China and expanding the commercial availability of the Lioli injector for EVO ICL procedures [13][14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the recovery in China and the potential for growth in 2026, despite ongoing macroeconomic challenges [9][78] - The company is not providing specific financial guidance for 2026 but expects to significantly increase sales compared to 2025 and target profitability [25][26] Other Important Information - The company has no debt and ended Q4 2025 with approximately $187.5 million in cash equivalents and investments [25] - The leadership structure has transitioned to a shared role of Interim Co-CEOs, focusing on continuity and alignment on priorities [5] Q&A Session Summary Question: Have the reductions in distributor inventory continued into the first quarter? - Management confirmed that inventory levels have stabilized and are below the six-month contractual level, indicating readiness for market recovery [31] Question: How does the health of the organization compare to pre-Alcon? - Management noted that expenses have been controlled since Q1 2025, and the organization is aligned around growth and profitability goals post-Alcon disruption [34] Question: What is the expected growth algorithm for 2026? - Management indicated that while they expect growth, it will not reach the hyper-growth levels seen in previous years, with a focus on restoring revenue and expanding profit margins [52] Question: What are the expectations for ICL and market growth in FY 2026? - Management expressed cautious optimism about further recovery in China, with Q4 2025 showing acceleration in market sales [78]

分组1 - Staar Surgical reported quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.16 per share, compared to a loss of $0.5 per share a year ago, representing an earnings surprise of -75.51% [1] - The company posted revenues of $57.8 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 23.6%, and compared to year-ago revenues of $48.95 million [2] - Staar Surgical shares have lost about 17.5% since the beginning of the year, while the S&P 500 has gained 0.5% [3] 分组2 - The current consensus EPS estimate for the coming quarter is $0.13 on $75.28 million in revenues, and $0.56 on $306.82 million in revenues for the current fiscal year [7] - The Medical - Dental Supplies industry, to which Staar Surgical belongs, is currently in the top 20% of over 250 Zacks industries, indicating a favorable outlook [8] - The Cooper Companies, another stock in the same industry, is expected to report quarterly earnings of $1.03 per share, representing a year-over-year change of +12% [9]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 e Form 10-K c (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended January 2, 2026 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-11634 STAAR SURGICAL COMPANY (Exact name of registrant as specified in its charter) Delaware 95-3797439 (State or other jurisdiction ...

Core Insights - STAAR Surgical (STAA) has received FDA approval to expand the age indication for its EVO/EVO+ Visian Implantable Collamer Lenses (EVO ICL) to patients aged 21 to 60 years, up from the previous limit of 21 to 45 years [1][9] Company Developments - The FDA approval is supported by three-year clinical trial data involving 629 eyes, showing a safety index of 1.25, with no cases of pupillary block or pigment dispersion, and a low incidence of anterior subcapsular cataract at 0.16% [2] - Management highlighted a significant shift in treatment paradigms, with a growing preference among surgeons for lens-based correction in high myopia, indicating that EVO ICL is central to future treatment pathways [4] - Following the announcement, STAA shares increased by 8.4%, although the stock has seen a decline of 37.2% over the past six months compared to the industry's 20.3% growth and the S&P 500's 8.8% rise [5][6] Market Trends - The U.S. refractive market is experiencing a decline in LASIK procedures, which have fallen nearly 40% over the past three years, while EVO ICL volumes are on the rise [10] - A recent survey indicated that 53% of U.S. vision correction consumers are considering alternatives to LASIK, reflecting a shift in patient preferences [10] - Management estimates that approximately 24 million myopic adults in the U.S., including 8 million aged 46-60, could be candidates for EVO ICL, positioning the product to capture a significant share of the refractive market [11] Industry Outlook - The intraocular lens market is projected to reach $5.34 billion by 2026, with a compound annual growth rate (CAGR) of 4.72% through 2035, driven by factors such as the rising prevalence of eye disorders and technological advancements [13]

Core Insights - Artificial intelligence (AI) is identified as the greatest investment opportunity of the current era, with a strong emphasis on the urgent need for energy to support its growth [1][2][3] - The demand for electricity from AI technologies, particularly data centers, is unprecedented, leading to concerns about power grid capacity and rising electricity prices [2][3] Investment Opportunity - A specific company is highlighted as a critical player in the AI energy sector, owning essential energy infrastructure assets that are poised to benefit from the increasing energy demands of AI [3][7] - This company is not a chipmaker or cloud platform but is positioned as a "toll booth" operator in the AI energy boom, collecting fees from energy exports and benefiting from the onshoring trend driven by tariffs [5][6] Financial Position - The company is noted for being debt-free and holding a significant cash reserve, amounting to nearly one-third of its market capitalization, which provides a strong financial foundation for growth [8][10] - It also has a substantial equity stake in another AI-related venture, offering investors indirect exposure to multiple growth opportunities without the associated premium costs [9][10] Market Trends - The article discusses the broader trends of AI, energy, tariffs, and onshoring, indicating that this company is well-positioned to capitalize on these interconnected developments [6][14] - The influx of talent into the AI sector is expected to drive continuous innovation and advancements, further solidifying the importance of investing in AI-related infrastructure [12] Future Outlook - The company is described as a key player in the future of clean and reliable power, particularly through its nuclear energy assets, which align with the evolving energy strategy in the U.S. [7][14] - The potential for significant returns is emphasized, with projections suggesting a possible 100% return within 12 to 24 months for investors who act now [15][19]